IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This clinical trial will investigate the effect of standardized Irvingia gabonensis extract (IGOB131) on GLP-1 dynamics, DPP-4 activity, metabolic parameters, and inflammatory markers in adults with obesity. The study will compare IGOB131 to a placebo to find out if it exerts any significant metabolic benefits through GLP-1 and DPP-4 modulation, and the reduction of adiposity and systemic inflammation. Participants will: Take IGOB131 or a placebo every day for 16 weeks Visit the clinic once every 4 weeks for checkups and tests
Epistemonikos ID: e6c986637ba9fd587b795104f9177e38b7698229
First added on: Oct 21, 2026